Practice parameter: Stroke prevention in patients with nonvalvular atrial fibrillation

Neurology

Volumn 51, Issue 3, 1998, Pages 671-673

  Greenberg, M K ^a   Franklin, G ^a   Alter, M ^a   Calverley, J ^a   Miller, R G ^a   French, J ^a   Ashwal, S ^a   Rosenberg, J H ^a   Zahn, C A ^a   Stevens, J ^a   Lanska, D J ^a   Mishra, S ^a   Odenheimer, G L ^a   Gronseth, G ^a   Dubinsky, R ^a   Hirtz, D ^a  

^a AMERICAN ACADEMY OF NEUROLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULATION; HEART ATRIUM FIBRILLATION; HIGH RISK POPULATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STROKE;

EID: 0031752371     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.51.3.671     Document Type: Review

References (16)

1. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Arch Intern Med 1995;155:469-473.
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. Arch Intern Med 1987; 147:1561-1564.
3. Sacco RL, Kargman DE, Zamanillo MC. Race-ethnic differences in stroke risk factors among hospitalized patients with cerebral infarction. Neurology 1995;45:659-663.
4. Furberg CD, Psaty BM, Manolio TA, et al. Prevalence of atrial fibrillation in elderly subjects (The Cardiovascular Health Study). Am J Cardiol 1994;74:236-241.
5. Miller VT, Rothrock JF, Pearce LA, Feinberg WM, Hart RG, Anderson DC. Ischemic stroke in patients with atrial fibrillation: effect of aspirin according to stroke mechanism. Neurology 1993;43:32-36.
6. Sandercock P, Bamford J, Dennis M, et al. Atrial fibrillation and stroke: prevalence in different types of stroke and influence on early and longterm prognosis. Br Med J 1992;305: 1460-1465.
7. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized clinical trials. Arch Intern Med 1994;154:1949-1957.
8. Stroke Prevention in Atrial Fibrillation Investigators. Risk factors for thromboembolism during aspirin therapy in atrial fibrillation. J Stroke Cerebrovasc Dis 1995;5:147-157.
9. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed- dose warfarin plus aspirin for high-risk patients with atrial fibrillation: The Stroke Prevention in Atrial Fibrillation III randomized clinical trial. Lancet 1996;348:633-638.
10. Hart RG, Sherman DG, Easton JD, Cairns JA. Prevention of stroke in patients with nonvalvular atrial fibrillation. Neurology 1998;51:674-681.
11. European Atrial Fibrillation Trial Study Group. Secondary prevention of vascular events in patients with nonrheumatic atrial fibrillation and recent transient ischemic attack or minor ischemic stroke. Lancet 1993;342:1255-1262.
12. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation. Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994;343:687-691.
13. Atrial Fibrillation Investigators. The efficacy of aspirin in patients with atrial fibrillation: analysis of pooled data from three randomized trials. Arch Intern Med 1997;157:1237-1240.
14. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335:540-546.
15. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120:897-902.
16. Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low-risk of stroke during treatment with aspirin. JAMA 1998;279:1273-1277.